Jazz Pharmaceuticals plc
NASDAQ:JAZZ · NASDAQ Global Select
+$0.05 today
Vol 1.91M · Avg 0.92M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-8.2%
avg 9.1%
ROIC
1.2%
avg 6.7%
ROA
-3.1%
avg 4.5%
Analysis
ROIC is currently the strongest return metric at 1.2% versus its period average of 6.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Renee D. Gala | President, Chief Executive Officer & Director | $3.01M | — | 54 | $152,196.00 | 0.24% |
Bruce C. Cozadd | Co-Founder & Chairman | $2.31M | — | 62 | $378,682.00 | 0.60% |
Robert Iannone | Executive Vice President, Chief Medical Officer and Global Head of Research & Development | $1.66M | — | 59 | $88,871.00 | 0.14% |
Philip L. Johnson | Executive Vice President & Chief Financial Officer | $1.50M | — | 61 | $59,608.00 | 0.09% |
Neena Patil | Executive Vice President & Chief Legal Officer | $1.46M | — | 51 | $51,549.00 | 0.08% |
Samantha Pearce | Executive Vice President & Chief Commercial Officer | $1.42M | — | 59 | $0.00 | <0.01% |
Patricia Carr | Senior Vice President & Chief Accounting Officer | $690,389.00 | — | 54 | $6,512.00 | 0.01% |
John D. Bluth | Head of Investor Relations | — | — | 53 | — | — |
Thomas J. Riga | Senior Vice President & Chief Business Officer | — | — | 50 | $14,663.00 | 0.02% |
Heidi Manna | Executive Vice President & Chief People Officer | — | — | 54 | — | — |
Mary Elizabeth Henderson | Senior Vice President of Technical Operations | — | — | 53 | $27,334.00 | 0.04% |
Jack W. Spinks | Executive Director of Investor Relations | — | — | — | — | — |
George Christopher Eliades | Senior Vice President & Chief Transformation Officer | — | — | 55 | $14,663.00 | 0.02% |
Jed Black | Senior Vice President of Sleep & CNS Medicine | — | — | — | — | — |
John Miller | Senior Vice President of Corporate Strategy | — | — | — | $22,118.00 | 0.04% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
52
$43.85M
Net Sentiment
$43.85M
Net selling
Most Active
COZADD BRUCE C
22 transactions
1–10 of 52
Analysis
Insiders reported 0 buys worth $0.00 and 52 sells worth $43.85M over the last 12 months. That adds up to net selling of $43.85M. COZADD BRUCE C was the most active insider with 22 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +3.0% | +13.2% (15yr)2 analysts |
| Revenue | N/A | N/A | +31.2% | +10.6% (15yr)15 analysts |
| Net Income | N/A | N/A | +4.5% | +13.0% (15yr)15 analysts |
| EBIT | N/A | N/A | +37.0% | +3.5% (15yr)15 analysts |
Analysis
Recent growth has been strongest in EBIT at +37.0% over three years. Forward estimates point to EPS at +13.2% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Axsome Therapeutics, Inc.
NASDAQ:AXSM
$12.98B
Madrigal Pharmaceuticals, Inc.
NASDAQ:MDGL
$11.52B
Cytokinetics, Incorporated
NASDAQ:CYTK
$9.72B
Nuvalent, Inc.
NASDAQ:NUVL
$9.07B
Halozyme Therapeutics, Inc.
NASDAQ:HALO
$8.13B
Merus N.V.
MRUS
$6.83B
Rhythm Pharmaceuticals, Inc.
NASDAQ:RYTM
$6.57B
Abivax S.A.
NASDAQ:ABVX
$6.57B
Caris Life Sciences, Inc.
NASDAQ:CAI
$5.05B
Atrium Therapeutics, Inc.
NASDAQ:RNA
$213.48M
Who manages JAZZ?
Jazz Pharmaceuticals plc (JAZZ) lists 15 active executives. The top listed executive is John D. Bluth, Head of Investor Relations.
Are JAZZ insiders buying or selling?
Recent insider activity shows net selling of $65.11M.
Explore More
Continue the stock analysis
Jump to another research area for this company.